EA029271B1 - Анти-hpg моноклональное антитело, полинуклеотид, кодирующий его цепи, экспрессионный вектор, клетка-хозяин, фармацевтическая композиция и набор, содержащие это моноклональное антитело, и способы его применения - Google Patents
Анти-hpg моноклональное антитело, полинуклеотид, кодирующий его цепи, экспрессионный вектор, клетка-хозяин, фармацевтическая композиция и набор, содержащие это моноклональное антитело, и способы его применения Download PDFInfo
- Publication number
- EA029271B1 EA029271B1 EA201200597A EA201200597A EA029271B1 EA 029271 B1 EA029271 B1 EA 029271B1 EA 201200597 A EA201200597 A EA 201200597A EA 201200597 A EA201200597 A EA 201200597A EA 029271 B1 EA029271 B1 EA 029271B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibody
- monoclonal antibody
- monoclonal antibodies
- lrs
- progastrin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/595—Gastrins; Cholecystokinins [CCK]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- General Engineering & Computer Science (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25262509P | 2009-10-16 | 2009-10-16 | |
| PCT/EP2010/006329 WO2011045080A2 (en) | 2009-10-16 | 2010-10-15 | Monoclonal antibodies to progastrin and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201200597A1 EA201200597A1 (ru) | 2012-12-28 |
| EA029271B1 true EA029271B1 (ru) | 2018-03-30 |
Family
ID=43086711
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201200597A EA029271B1 (ru) | 2009-10-16 | 2010-10-15 | Анти-hpg моноклональное антитело, полинуклеотид, кодирующий его цепи, экспрессионный вектор, клетка-хозяин, фармацевтическая композиция и набор, содержащие это моноклональное антитело, и способы его применения |
| EA201791876A EA201791876A1 (ru) | 2009-10-16 | 2010-10-15 | Моноклональные антитела к прогастрину и их применение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791876A EA201791876A1 (ru) | 2009-10-16 | 2010-10-15 | Моноклональные антитела к прогастрину и их применение |
Country Status (42)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
| US8136651B2 (en) * | 2007-12-14 | 2012-03-20 | The Procter & Gamble Company | Method and apparatus for orienting articles |
| IN2012DN03348A (https=) * | 2009-10-16 | 2015-10-23 | Biorealites | |
| US8900588B2 (en) * | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Methods for treating breast cancer |
| US8900817B2 (en) | 2010-01-08 | 2014-12-02 | Les Laboratories Servier | Progastrin and liver pathologies |
| ES2754774T3 (es) * | 2010-03-24 | 2020-04-20 | Progastrine Et Cancers S A R L | Profilaxis de cáncer colorrectal y gastrointestinal |
| CA2806157C (en) * | 2010-07-26 | 2016-11-22 | Les Laboratoires Servier | Methods and compositions for liver cancer therapy |
| US8785603B2 (en) | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
| EP2715364A1 (en) | 2011-06-01 | 2014-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for predicting the risk of developing a colonic neoplasia |
| JP6450381B2 (ja) * | 2013-07-05 | 2019-01-09 | ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション | がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体 |
| BR112016024214B8 (pt) * | 2014-04-18 | 2023-12-26 | Univ New York State Res Found | Anticorpo monoclonal parcialmente humanizado, composição farmacêutica e uso de um anticorpo monoclonal |
| US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
| WO2016066671A1 (en) | 2014-10-29 | 2016-05-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for treating resistant cancers using progastrin inhibitors |
| EP3349768A4 (en) * | 2015-09-15 | 2019-01-23 | The Scripps Research Institute | ANTIBODIES FOR THE PRODUCTION OF ANTI-INFLAMMATORY MACROPHAGES AND CORRESPONDING USES |
| SG11201805605TA (en) * | 2015-12-31 | 2018-07-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating ovarian cancer |
| EP3954998B1 (en) * | 2015-12-31 | 2024-12-25 | ECS-Progastrin SA | Compositions and methods for detecting and treating gastric cancer |
| JP6940505B2 (ja) * | 2015-12-31 | 2021-09-29 | シンセラス、エス、アー エル、エルＳｙｎｃｅｒｕｓ Ｓ．Ａ Ｒ．Ｌ． | 組成物および癌の発生リスクの評価方法 |
| CN110662769B (zh) * | 2017-03-30 | 2023-10-20 | 普莱戈斯瑞恩癌症有限责任公司 | 使用前胃泌素结合分子检测和治疗前列腺癌的组合物和方法 |
| US11561225B2 (en) * | 2017-03-30 | 2023-01-24 | Progastrine Et Cancers S.À R.L. | Compositions and methods for treating lung cancer |
| DK3720879T3 (da) * | 2017-12-05 | 2022-06-20 | Progastrine Et Cancers S A R L | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer |
| WO2019110845A1 (en) | 2017-12-08 | 2019-06-13 | Ecs-Biotracker Sàrl | Radiolabeled progastrin in cancer diagnosis |
| WO2019145537A1 (en) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combination of progastrin detection with other cancer biomarkers in cancer diagnosis |
| AU2019228339B2 (en) * | 2018-02-27 | 2025-02-27 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
| TWI793238B (zh) * | 2018-12-27 | 2023-02-21 | 偉喬生醫股份有限公司 | 體外檢測生物樣品之胃源性蛋白的方法及套組 |
| WO2021066751A1 (en) * | 2019-10-02 | 2021-04-08 | Aslan Pharmaceuticals Pte. Ltd. | Antigen specific binding domains and antibody molecules |
| CN112062846A (zh) * | 2020-04-27 | 2020-12-11 | 杭州博茵生物技术有限公司 | 一种g-17单克隆抗体及其应用 |
| CN115785273B (zh) * | 2021-09-10 | 2023-10-31 | 东莞市朋志生物科技有限公司 | 一种抗胃蛋白酶原i的抗体及其应用 |
| CN115724949A (zh) * | 2022-12-12 | 2023-03-03 | 郑州伊美诺生物技术有限公司 | 一种鼠源lgG单克隆抗体及其制备方法、应用 |
| CN116143920A (zh) * | 2022-12-30 | 2023-05-23 | 南京岚煜生物科技有限公司 | 胃泌素17的单克隆抗体及其细胞株的制备方法和应用 |
| EP4509528A1 (en) * | 2023-08-16 | 2025-02-19 | Barrelman Biosciences LLC | Monoclonal antibodies against veterinary progastrin-like molecules and their uses |
| CN118126177A (zh) * | 2023-11-22 | 2024-06-04 | 艾维可生物科技有限公司 | 抗成熟型胃泌素17的单克隆抗体及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006032980A1 (en) * | 2004-09-22 | 2006-03-30 | Receptor Biologix, Inc. | Monoclonal antibolies to progastrin |
| WO2007135542A2 (en) * | 2006-05-22 | 2007-11-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Progastrin inhibitors in the treatment of colon cancer |
| WO2008076454A1 (en) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| WO2010037395A2 (en) * | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| IN2012DN03348A (https=) * | 2009-10-16 | 2015-10-23 | Biorealites | |
| ES2754774T3 (es) * | 2010-03-24 | 2020-04-20 | Progastrine Et Cancers S A R L | Profilaxis de cáncer colorrectal y gastrointestinal |
| CA2806157C (en) * | 2010-07-26 | 2016-11-22 | Les Laboratoires Servier | Methods and compositions for liver cancer therapy |
-
2010
- 2010-10-15 IN IN3348DEN2012 patent/IN2012DN03348A/en unknown
- 2010-10-15 AP AP2012006262A patent/AP2012006262A0/xx unknown
- 2010-10-15 KR KR1020127012677A patent/KR20120091221A/ko not_active Ceased
- 2010-10-15 KR KR1020157017085A patent/KR101640520B1/ko active Active
- 2010-10-15 NZ NZ599971A patent/NZ599971A/en unknown
- 2010-10-15 WO PCT/EP2010/006329 patent/WO2011045080A2/en not_active Ceased
- 2010-10-15 LT LTEP10768878.0T patent/LT2488551T/lt unknown
- 2010-10-15 UA UAA201205759A patent/UA106771C2/uk unknown
- 2010-10-15 HR HRP20181645TT patent/HRP20181645T1/hr unknown
- 2010-10-15 RS RS20181241A patent/RS57966B1/sr unknown
- 2010-10-15 SG SG10201704933PA patent/SG10201704933PA/en unknown
- 2010-10-15 TW TW099135321A patent/TWI537002B/zh active
- 2010-10-15 EA EA201200597A patent/EA029271B1/ru not_active IP Right Cessation
- 2010-10-15 JP JP2012533531A patent/JP5985987B2/ja active Active
- 2010-10-15 PT PT10768878T patent/PT2488551T/pt unknown
- 2010-10-15 BR BR112012008818-1A patent/BR112012008818B1/pt active IP Right Grant
- 2010-10-15 CN CN201080057237.3A patent/CN102791735B/zh active Active
- 2010-10-15 GE GEAP201012707A patent/GEP201706604B/en unknown
- 2010-10-15 PE PE2012000434A patent/PE20121649A1/es active IP Right Grant
- 2010-10-15 SI SI201031788T patent/SI2488551T1/sl unknown
- 2010-10-15 AU AU2010306119A patent/AU2010306119A1/en not_active Abandoned
- 2010-10-15 CN CN201410752851.1A patent/CN104628857A/zh active Pending
- 2010-10-15 EP EP18185172.6A patent/EP3421493B1/en active Active
- 2010-10-15 CA CA2777691A patent/CA2777691C/en active Active
- 2010-10-15 AR ARP100103784A patent/AR078659A1/es active IP Right Grant
- 2010-10-15 SM SM20180628T patent/SMT201800628T1/it unknown
- 2010-10-15 EP EP10768878.0A patent/EP2488551B1/en active Active
- 2010-10-15 PH PH1/2012/500711A patent/PH12012500711B1/en unknown
- 2010-10-15 NZ NZ701709A patent/NZ701709A/en unknown
- 2010-10-15 PL PL18185172.6T patent/PL3421493T3/pl unknown
- 2010-10-15 PL PL10768878T patent/PL2488551T3/pl unknown
- 2010-10-15 US US12/906,041 patent/US9611320B2/en active Active
- 2010-10-15 EA EA201791876A patent/EA201791876A1/ru unknown
- 2010-10-15 ES ES10768878.0T patent/ES2690943T3/es active Active
- 2010-10-15 MX MX2012004400A patent/MX351635B/es active IP Right Grant
- 2010-10-15 ES ES18185172T patent/ES2973217T3/es active Active
- 2010-10-15 DK DK10768878.0T patent/DK2488551T3/en active
-
2012
- 2012-04-03 IL IL219019A patent/IL219019B/en active IP Right Grant
- 2012-04-04 TN TNP2012000159A patent/TN2012000159A1/en unknown
- 2012-04-11 CL CL2012000914A patent/CL2012000914A1/es unknown
- 2012-04-12 ZA ZA2012/02642A patent/ZA201202642B/en unknown
- 2012-04-13 EC ECSP12011796 patent/ECSP12011796A/es unknown
- 2012-04-13 HN HN2012000708A patent/HN2012000708A/es unknown
- 2012-04-13 CR CR20120184A patent/CR20120184A/es unknown
- 2012-04-13 NI NI201200054A patent/NI201200054A/es unknown
- 2012-04-16 GT GT201200114A patent/GT201200114A/es unknown
- 2012-04-16 CU CUP2012000060A patent/CU24196B1/es active IP Right Grant
- 2012-05-11 MA MA34864A patent/MA33747B1/fr unknown
-
2015
- 2015-03-04 JP JP2015042849A patent/JP6272793B2/ja active Active
-
2017
- 2017-03-06 US US15/451,253 patent/US10385124B2/en active Active
- 2017-03-06 US US15/451,280 patent/US10385126B2/en active Active
- 2017-03-06 US US15/451,275 patent/US10377821B2/en active Active
- 2017-03-06 US US15/451,268 patent/US10385125B2/en active Active
- 2017-06-21 JP JP2017121372A patent/JP2017212992A/ja active Pending
- 2017-08-15 IL IL254004A patent/IL254004B2/en unknown
-
2018
- 2018-10-22 CY CY181101081T patent/CY1120913T1/el unknown
-
2019
- 2019-06-28 US US16/456,328 patent/US11299542B2/en active Active
-
2022
- 2022-03-07 US US17/687,909 patent/US20220195035A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006032980A1 (en) * | 2004-09-22 | 2006-03-30 | Receptor Biologix, Inc. | Monoclonal antibolies to progastrin |
| WO2007135542A2 (en) * | 2006-05-22 | 2007-11-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Progastrin inhibitors in the treatment of colon cancer |
| WO2008076454A1 (en) * | 2006-12-19 | 2008-06-26 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
Non-Patent Citations (4)
| Title |
|---|
| HORNBECK P ET AL: "Enzyme-linked immunosorbent assays (ELISA).", CURRENT PROTOCOLS IN MOLECULAR BIOLOGY., WILEY, vol. Chapter 11, 1 May 2001 (2001-05-01), pages Unit11.2, XP002477297, DOI: 10.1002/0471142727.mb1102s15 * |
| LARRICK J. W., ET AL.: "POLYMERASE CHAIN REACTION USING MIXED PRIMERS: CLONING OF HUMAN MONOCLONAL ANTIBODY VARIABLE REGION GENES FROM SINGLE HYBRIDOMA CELLS.", BIOTECHNOLOGY. THE INTERNATIONAL MONTHLY FOR INDUSTRIAL BIOLOGY, NATURE PUBLISHING GROUP, US, vol. 07., 1 September 1989 (1989-09-01), US, pages 934 - 938., XP000400715, ISSN: 0733-222X, DOI: 10.1038/nbt0989-934 * |
| LARRICK J. W., ET AL.: "RAPID CLONING OF REARRANGED IMMUNOGLOBULIN GENES FROM HUMAN HYBRIDOMA CELLS USING MIXED PRIMERS AND THE POLYMERASE CHAIN REACTION.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 160., no. 03., 15 May 1989 (1989-05-15), pages 1250 - 1256., XP000293053, ISSN: 0006-291X, DOI: 10.1016/S0006-291X(89)80138-X * |
| TOLEIKIS L, BRODERS O, DUEBEL S: "CLONING SINGLE-CHAIN ANTIBODY FRAGMENTS (SCFV) FROM HYBRIDOMA CELLS", METHODS IN MOLECULAR MEDICINE, vol. 94, 1 January 2004 (2004-01-01), pages 447 - 458, XP008045594, ISSN: 1543-1894 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA029271B1 (ru) | Анти-hpg моноклональное антитело, полинуклеотид, кодирующий его цепи, экспрессионный вектор, клетка-хозяин, фармацевтическая композиция и набор, содержащие это моноклональное антитело, и способы его применения | |
| EA028515B1 (ru) | Способы и композиции для терапии рака печени | |
| EA026944B1 (ru) | Применение антитела к человеческому прогастрину для приготовления лекарственного средства для лечения колоректального рака и способы лечения метастатического колоректального рака (варианты) | |
| US8383123B2 (en) | Method of treatment targeting HEPSIN | |
| AU2014203017B2 (en) | Monoclonal antibodies to progastrin and their uses | |
| HK40002657B (en) | Monoclonal antibodies to progastrin and their uses | |
| HK40002657A (en) | Monoclonal antibodies to progastrin and their uses | |
| EA041823B1 (ru) | Моноклональные антитела к прогастрину и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |